77 related articles for article (PubMed ID: 10928088)
21. [Effect of tamoxifen plus octreotide on DMBA-induced mammary tumors in rats].
Zeng XZ; Yao ZX
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):28-32. PubMed ID: 15808071
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
23. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
24. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
25. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo.
Chen H; Takahashi S; Imamura M; Okutani E; Zhang ZG; Chayama K; Chen BA
Chin Med J (Engl); 2007 May; 120(10):898-904. PubMed ID: 17543180
[TBL] [Abstract][Full Text] [Related]
26. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
Bouin M; Aoust LD
Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
[TBL] [Abstract][Full Text] [Related]
27. Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro.
Huang Z; Guo KJ; Guo RX; He SG
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):312-20. PubMed ID: 17548258
[TBL] [Abstract][Full Text] [Related]
28. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo.
Jia WD; Xu GL; Sun HC; Wang L; Xu RN; Xue Q
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):404-9. PubMed ID: 14599948
[TBL] [Abstract][Full Text] [Related]
29. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
30. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
31. [Effect of sandostatin on the growth of transplantable pancreatic tumors in rats].
Damge C; Hajri A; Aprahamian M; Vonderscher J
Bull Cancer; 1989; 76(8):843-4. PubMed ID: 2620110
[No Abstract] [Full Text] [Related]
32. G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model.
Dekoj T; Lee S; Desai S; Trevino J; Babcock TA; Helton WS; Espat NJ
J Surg Res; 2007 May; 139(1):106-12. PubMed ID: 17291531
[TBL] [Abstract][Full Text] [Related]
33. Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity.
Bocsi J; Zalatnai A
J Cancer Res Clin Oncol; 1999; 125(1):9-19. PubMed ID: 10037272
[TBL] [Abstract][Full Text] [Related]
34. In vitro antiangiogenic effect of sandostatin (octreotide) on the proliferation of the placental vessels.
Zalatnai A; Timár F
Anticancer Res; 2002; 22(6C):4225-7. PubMed ID: 12553061
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis of Verner-Morrison syndrome (VDHA) and its treatment with sandostatin an streptozocitin].
Várkonyi TT; Velösy B; Nagy I; Németh J; Lonovics J
Orv Hetil; 1993 Nov; 134(47):2599-602. PubMed ID: 8247522
[TBL] [Abstract][Full Text] [Related]
36. [The use of Sandostatin in the combined treatment of surgical diseases of the pancreas].
Saenko VF; Lifshits IuZ; Kozhara SP; Usenko AIu; Andreeshchev SA; Kryzhevskiĭ VV; Olenin VV; Beliaeva OA
Lik Sprava; 1997; (3):126-7. PubMed ID: 9377332
[TBL] [Abstract][Full Text] [Related]
37. Sandostatin and the Hammersmith experience.
Wynick D; Bloom SR
Digestion; 1990; 45 Suppl 1():5-9; discussion 9-10. PubMed ID: 2335269
[TBL] [Abstract][Full Text] [Related]
38. [Sandostatin treatment of destructive pancreatitis].
Ivanov IuV
Klin Med (Mosk); 1999; 77(9):37-9. PubMed ID: 10599225
[TBL] [Abstract][Full Text] [Related]
39. Preclinical studies on the anticancer activity of the somatostatin analog octreotide (SMS 201-995).
Weckbecker G; Tolcsvai L; Liu R; Bruns C
Digestion; 1993; 54 Suppl 1():98-103. PubMed ID: 8359575
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic cancer: does octreotide offer any promise?
Rosenberg L
Chemotherapy; 2001; 47 Suppl 2():134-49. PubMed ID: 11275707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
